Cystic fibrosis related diabetes (CFRD) is a distinct form of diabetes that is associated with
significantly increased morbidity and mortality in the CF population. The primary etiology is …

Pancreatic α-cells are the major source of glucagon, a hormone that counteracts the
hypoglycemic action of insulin and strongly contributes to the correction of acute …

Cystic fibrosis–related (CF-related) diabetes (CFRD) is an increasingly common and
devastating comorbidity of CF, affecting approximately 35% of adults with CF. However, the …

Glucagon is the body's main hyperglycemic hormone, and its secretion is dysregulated in
type 2 diabetes mellitus (T2 DM). The incretin hormone glucagon‐like peptide‐1 (GLP‐1) is …

Background The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose
tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We …

Rationale: Diabetes is associated with worse cystic fibrosis (CF) outcomes. The CFTR
potentiator ivacaftor is suggested to improve glucose homeostasis in individuals with CF …

Cystic fibrosis (CF) is a recessive disorder arising from mutations in the gene encoding the
cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is expressed in …

The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes
in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung …

Diabetes mellitus, a disease that affects nearly 536.6 million people worldwide, is
characterized by the death or dysfunction of insulin-producing beta cells of the pancreas …

The development and introduction of modulator therapies have completely shifted the
paradigm for the treatment of cystic fibrosis (CF). Highly effective modulator therapies have …